Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: lonzabioscience.com.au
Phone: 1300 657508

Content from other channels on our network

Tallawang Solar Hybrid project secures access rights

CSIRO announces ON Accelerate project teams

SEW Water Saver App recognised as awards finalist

How AI-powered bushfire detection can protect forests and communities

Industrias partners with Microgrid Power to maintain solar

PE20 Palletising System by Optima Robotics

Snackfood development: protein puffs that are easy to swallow

China's new food colouring standard welcomed by industry

Bega to close Strathmerton cheese processing plant by mid-2026

Fonterra invests a further $70m to move away from coal

'Enhanced cleaning' cuts hospital-acquired infections by one-third

Perioperative nurses take on surgical escape room

Victoria's Q3 median ED wait times the lowest on record

Biophilic healing: expanded Latrobe Regional Hospital, Traralgon

Nominations open for 2025 National Palliative Care Awards

Lonza bone marrow and cord blood mononuclear cells

Cayman Chemical Kinase Screening Library (96-Well)

AdipoGen Life Sciences GLP-1, GIP and GCG receptor agonists

Integrated DNA Technologies xGen Hybridization and Wash v3 Kit

Content from other channels on our network